AUS
NZ
UK
CA
USA
IND
Highlights
- Aroa Biosurgery sees strong revenue growth and reduced cash outflow.
- Key products like Myriad and OviTex continue to drive sales across multiple regions.
- Regulatory approvals and clinical evidence bolster ARX's market position.
Aroa Biosurgery (ASX:ARX) has reported impressive financial performance for the quarter, with cash receipts from customers totaling NZ$19.9 million, representing a significant year-over-year and quarter-over-quarter increase. This growth was primarily driven by the strong sales of its flagship products, Myriad, OviTex, and OviTex PRS, all of which are used in various surgical procedures requiring tissue reconstruction.
The ASX healthcare stock Aroa's Myriad product family continues to perform well, supporting various surgical applications. Aroa’s OviTex and OviTex PRS bioscaffolds, co-developed with TELA Bio, are driving sales in the US and Europe. These products focus on abdominal wall reconstruction, hernia repair, and breast reconstruction, with OviTex PRS being a recent addition to the lineup.
In line with expectations, the company reported a reduction in net cash outflow from operations, decreasing by NZ$2.4 million to NZ$1.2 million for the quarter. Despite the ongoing expenses associated with the Symphony randomised controlled trial, Aroa Biosurgery managed to improve its cash flow position, reflecting increased customer receipts.
The Symphony trial, involving approximately 120 patients, is focused on evaluating the efficacy of Aroa’s product for treating diabetic foot ulcers and other chronic wounds. The company expects that data from this 18-month study, due to be published in FY25, will be a key driver for future growth in Symphony sales. Additionally, the company is on track to achieve positive cash flow from operations by the second half of FY25.
Net cash outflow from investing activities was reported at NZ$600,000 for the quarter, mostly attributed to routine capital expenditure. Aroa Biosurgery also saw a sharp decrease in its quarterly cash burn, down to NZ$2.2 million, ending the period with a strong cash balance of NZ$21.6 million and no outstanding debt. The company has maintained its revenue guidance for FY25 at NZ$80-87 million, with an expected EBITDA profit of NZ$2-6 million.
Momentum is building in the US for Aroa’s commercial operations, with the company restructuring its sales leadership to accommodate growth. Regional manager Mark Maerten was promoted to national sales director, and two new territories were added. This reconfiguration is aimed at increasing productivity and further boosting sales growth. In the US, active Myriad accounts saw a 5% quarter-over-quarter increase.
During the quarter, Aroa Biosurgery achieved regulatory approval for its Endoform and Myriad Matrix products in Argentina and Egypt. These approvals will enable the company to expand its market reach for products used in wound care and tissue reconstruction. Additionally, four peer-reviewed studies were published, supporting the efficacy of Aroa’s ECM-based products. One study highlighted the superior structural properties of Aroa’s ECM technology compared to other commercially available products.
Aroa’s teams also actively participated in key industry events, including the American Association for the Surgery of Trauma Annual Meeting and the International Society for Burns Biennial Congress, further solidifying the company’s presence in the global medical community.
